Book contents
- Rethinking Clinical Research
- Rethinking Clinical Research
- Copyright page
- Contents
- Acknowledgments
- Introduction
- Part I Fundamentals
- Part II Rethinking Research
- Part III Case Studies
- 13 Case Study: Treating Gastroesophageal Reflux Disease with Omeprazole
- 14 Case Study: Statin Therapy for Primary Prevention of Heart Disease
- 15 Case Study: Cancer Screening
- 16 Case Study: Antidepressant Medications
- Conclusions and Recommendations
- Index
- References
13 - Case Study: Treating Gastroesophageal Reflux Disease with Omeprazole
from Part III - Case Studies
Published online by Cambridge University Press: aN Invalid Date NaN
Book contents
- Rethinking Clinical Research
- Rethinking Clinical Research
- Copyright page
- Contents
- Acknowledgments
- Introduction
- Part I Fundamentals
- Part II Rethinking Research
- Part III Case Studies
- 13 Case Study: Treating Gastroesophageal Reflux Disease with Omeprazole
- 14 Case Study: Statin Therapy for Primary Prevention of Heart Disease
- 15 Case Study: Cancer Screening
- 16 Case Study: Antidepressant Medications
- Conclusions and Recommendations
- Index
- References
Summary
Gastroesophageal reflux disease is a common condition that can be controlled with proton pump inhibitors such as omeprazole. We examine randomized controlled trials (RCTs) of omeprazole and find stronger evidence of efficacy among RCTs with industry support than without. The participants in these trials were unlike most people who take proton pump inhibitors, raising questions about the external validity of RCTs. Furthermore, use of these medicines is associated with short- and longer-term adverse effects. Healthy behavior change, such as weight loss, holds promise as an alternative to proton pump inhibitors.
Keywords
- Type
- Chapter
- Information
- Rethinking Clinical ResearchMethodology and Ethics, pp. 253 - 272Publisher: Cambridge University PressPrint publication year: 2025
References
Zhang, D, Liu, S, Li, Z, Wang, R. Global, regional and national burden of gastroesophageal reflux disease, 1990–2019: Update from the GBD 2019 study. Ann Med. 2022; 54(1):1372–1384. doi:10.1080/07853890.2022.2074535.CrossRefGoogle ScholarPubMed
El-Serag, HB, Sweet, S, Winchester, CC, Dent, J. Update on the epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut. 2014; 63(6):871–880. doi:10.1136/gutjnl-2012-304269.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Health, United States, 2016 – Individual Charts and Tables: Spreadsheet, PDF, and PowerPoint files. Table 80. Selected prescription drug classes used in the past 30 days, by sex and age: United States, selected years 1988–1994 through 2011–2014. 2016. www.cdc.gov/nchs/data/hus/2016/080.pdf.Google Scholar
Targownik, LE, Fisher, DA, Saini, SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology. 2022; 162(4):1334–1342. doi:10.1053/j.gastro.2021.12.247.CrossRefGoogle ScholarPubMed
Barberio, B, Visaggi, P, Savarino, E, de Bortoli, N, Black, CJ, Ford, AC. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network meta-analysis. Neurogastroenterol Motil. 2023; 35(1):e14469. doi:10.1111/nmo.14469.CrossRefGoogle ScholarPubMed
Elliott, N, Steel, A, Leech, B, Peng, W. Design characteristics of comparative effectiveness trials for the relief of symptomatic dyspepsia: A systematic review. Integr Med Res. 2021; 10(2):100663. doi:10.1016/j.imr.2020.100663.CrossRefGoogle ScholarPubMed
Chiu, CT, Hsu, CM, Wang, CC, et al. Randomised clinical trial: Sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013; 38(9):1054–1064. doi:10.1111/apt.12482.CrossRefGoogle ScholarPubMed
Manabe, N, Haruma, K, Ito, M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: A randomized clinical trial. Dis Esophagus. 2012; 25(5):373–380. doi:10.1111/j.1442-2050.2011.01276.x.CrossRefGoogle ScholarPubMed
Hosseini, M, Salari, R, Akbari Rad, M, Salehi, M, Birjandi, B, Salari, M. Comparing the effect of psyllium seed on gastroesophageal reflux disease with oral omeprazole in patients with functional constipation. J Evid Based Integr Med. 2018; 23:2515690X18763294. doi:10.1177/2515690X18763294.CrossRefGoogle ScholarPubMed
Armstrong, D, Talley, NJ, Lauritsen, K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: The effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004; 20(4):413–421. doi:10.1111/j.1365-2036.2004.02085.x.CrossRefGoogle ScholarPubMed
Bate, CM, Griffin, SM, Keeling, PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996; 10(4):547–555. doi:10.1046/j.1365-2036.1996.44186000.x.CrossRefGoogle ScholarPubMed
Bate, CM, Green, JR, Axon, AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997; 11(4):755–763. doi:10.1046/j.1365-2036.1997.00198.x.CrossRefGoogle ScholarPubMed
Carlsson, R, Dent, J, Watts, R, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998; 10(2):119–124.CrossRefGoogle Scholar
Fujiwara, Y, Higuchi, K, Nebiki, H, et al. Famotidine vs. omeprazole: A prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005; 21(Suppl 2):10–18. doi:10.1111/j.1365-2036.2005.02468.x.CrossRefGoogle ScholarPubMed
Lind, T, Havelund, T, Carlsson, R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997; 32(10):974–979. doi:10.3109/00365529709011212.CrossRefGoogle ScholarPubMed
Richter, JE, Peura, D, Benjamin, SB, Joelsson, B, Whipple, J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000; 160(12):1810–1816. doi:10.1001/archinte.160.12.1810.CrossRefGoogle ScholarPubMed
Uemura, N, Inokuchi, H, Serizawa, H, et al. Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. J Gastroenterol. 2008; 43(9):670–678. doi:10.1007/s00535-008-2214-5.CrossRefGoogle ScholarPubMed
Venables, TL, Newland, RD, Patel, AC, Hole, J, Wilcock, C, Turbitt, ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997; 32(10):965–973. doi:10.3109/00365529709011211.CrossRefGoogle ScholarPubMed
Cohen, J. A power primer. Psychol Bull. 1992; 112(1):155–159. doi:10.1037//0033-2909.112.1.155.CrossRefGoogle ScholarPubMed
Drug Discovery Online. Patent expiry looms: 18 blockbusters expose $37 billion to generic competition by 2005. 2000.Google Scholar
Food and Drug Administration. Drug Approval Package: Nexium (Esomeprazole Magnesium) Delayed-Release Capsules. 2001.Google Scholar
Abramson, J. Sickening: How Big Pharma Broke American Health Care and How We Can Repair It. Mariner Books; 2022.Google Scholar
Fass, R, Boeckxstaens, GE, El-Serag, H, Rosen, R, Sifrim, D, Vaezi, MF. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021; 7(1):55. doi:10.1038/s41572-021-00287-w.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Lindam, A, Lagergren, J, Hveem, K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: The HUNT study. Am J Gastroenterol. 2013; 108(3):376–382. doi:10.1038/ajg.2012.466.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Lindam, A, Lagergren, J, Hveem, K. Tobacco smoking cessation and improved gastroesophageal reflux: A prospective population-based cohort study: The HUNT study. Am J Gastroenterol. 2014; 109(2):171–177. doi:10.1038/ajg.2013.414.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Hveem, K, El-Serag, H, Lagergren, J. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2016; 14(2):175–182.e1–e3. doi:10.1016/j.cgh.2015.04.176.CrossRefGoogle ScholarPubMed
Ness-Jensen, E, Lagergren, J. Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2017; 31(5):501–508. doi:10.1016/j.bpg.2017.09.004.CrossRefGoogle ScholarPubMed
Eusebi, LH, Ratnakumaran, R, Yuan, Y, Solaymani-Dodaran, M, Bazzoli, F, Ford, AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018; 67(3):430–440. doi:10.1136/gutjnl-2016-313589.CrossRefGoogle ScholarPubMed
National Institute of Heart, Lung, and Blood. Calculate your body mass index. Accessed July 23, 2023. www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi-m.htm.Google Scholar
Boeckxstaens, G, El-Serag, HB, Smout, AJ, Kahrilas, PJ. Symptomatic reflux disease: The present, the past and the future. Gut. 2014; 63(7):1185–1193. doi:10.1136/gutjnl-2013-306393.CrossRefGoogle ScholarPubMed
Lu, B, Zhang, L, Wang, J, et al. Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study). J Gastroenterol Hepatol. 2018; 33(10):1722–1727. doi:10.1111/jgh.14143.CrossRefGoogle Scholar
Jain, S, Shamrao Kulkarni, S, Mahapatra, JR, et al. Effectiveness of omeprazole in acid peptic disease: A real-world, patient-reported outcome measures study. Cureus. 2023; 15(7):e41994. doi:10.7759/cureus.41994.Google ScholarPubMed
Yadlapati, R, Gyawali, CP, Pandolfino, JE, Participants, CGCC. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: Expert review. Clin Gastroenterol Hepatol. 2022; 20(5):984–994.e1. doi:10.1016/j.cgh.2022.01.025.CrossRefGoogle Scholar
Ware, JE, Snow, KK, Kosinski, M, Gandek, B. SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center; 1993.Google Scholar
Wiklund, IK, Junghard, O, Grace, E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl. 1998; 583:41–49.Google Scholar
Talley, NJ, Wiklund, I. Patient reported outcomes in gastroesophageal reflux disease: An overview of available measures. Qual Life Res. 2005; 14(1):21–33. doi:10.1007/s11136-004-0613-5.CrossRefGoogle ScholarPubMed
Prasad, M, Rentz, AM, Revicki, DA. The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: A literature review. Pharmacoeconomics. 2003; 21(11):769–790. doi:10.2165/00019053-200321110-0002.CrossRefGoogle ScholarPubMed
Kamolz, T, Pointner, R, Velanovich, V. The impact of gastroesophageal reflux disease on quality of life. Surg Endosc. 2003; 17(8):1193–1199. doi:10.1007/s00464-002-9229-4.CrossRefGoogle ScholarPubMed
Velanovich, V. Quality of life and severity of symptoms in gastro-oesophageal reflux disease: A clinical review. Eur J Surg. 2000;166(7):516–525. doi:10.1080/110241500750008565.CrossRefGoogle ScholarPubMed
El-Dika, S, Guyatt, GH, Armstrong, D, et al. The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol. 2005; 5:23. doi:10.1186/1471-230X-5-23.CrossRefGoogle ScholarPubMed
Wahlqvist, P. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol. 2001; 96(8 Suppl):S57–S61. doi:10.1016/s0002-9270(01)02590-4.CrossRefGoogle ScholarPubMed
Mokrowiecka, A, Jurek, K, Pińkowski, D, Małecka-Panas, E. The comparison of Health-Related Quality of Life (HRQL) in patients with GERD, peptic ulcer disease and ulcerative colitis. Adv Med Sci. 2006; 51:142–147.Google ScholarPubMed
Revicki, DA, Wood, M, Maton, PN, Sorensen, S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998; 104(3):252–258. doi:10.1016/s0002-9343(97)00354-9.CrossRefGoogle ScholarPubMed
Fallone, CA, Guyatt, GH, Armstrong, D, et al. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2004; 20(10):1161–1169. doi:10.1111/j.1365-2036.2004.02257.x.CrossRefGoogle ScholarPubMed
Schünemann, HJ, Armstrong, D, Degl’innocenti, A, et al. A randomized multicenter trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care. 2004; 42(11):1132–1142. doi:10.1097/00005650-200411000-00013.CrossRefGoogle ScholarPubMed
Kaplan-Machlis, B, Spiegler, GE, Zodet, MW, Revicki, DA. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000; 9(7):624–630. doi:10.1001/archfami.9.7.624.CrossRefGoogle ScholarPubMed
Aimi, M, Komazawa, Y, Hamamoto, N, et al. Effects of omeprazole on sleep disturbance: Randomized multicenter double-blind placebo-controlled trial. Clin Transl Gastroenterol. 2014; 5(6):e57. doi:10.1038/ctg.2014.8.CrossRefGoogle ScholarPubMed
Chan, Y, Ching, JY, Cheung, CM, et al. Development and validation of a disease-specific quality of life questionnaire for gastro-oesophageal reflux disease: The GERD-QOL questionnaire. Aliment Pharmacol Ther. 2010; 31(3):452–460. doi:10.1111/j.1365-2036.2009.04187.x.CrossRefGoogle ScholarPubMed
Feeny, D, Furlong, W, Torrance, GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002; 40(2):113–128.CrossRefGoogle ScholarPubMed
Kaplan, RM, Ganiats, TG, Sieber, WJ, Anderson, JP. The Quality of Well-Being Scale: Critical similarities and differences with SF-36. Int J Qual Health Care. 1998; 10(6):509–520.CrossRefGoogle ScholarPubMed
Furlong, WJ, Feeny, DH, Torrance, GW, Barr, RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001; 33(5):375–384. doi:10.3109/07853890109002092.CrossRefGoogle ScholarPubMed
Kartman, B. Utility and willingness to pay measurements among patients with gastroesophageal reflux disease. Am J Gastroenterol. 2001; 96(8 Suppl):S38–S43. doi:10.1016/s0002-9270(01)02581-3.CrossRefGoogle ScholarPubMed
Heudebert, GR, Marks, R, Wilcox, CM, Centor, RM. Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis. Gastroenterology. 1997; 112(4):1078–1086. doi:10.1016/s0016-5085(97)70118-5.CrossRefGoogle ScholarPubMed
Goeree, R, Hopkins, R, Marshall, JK, et al. Cost-utility of laparoscopic Nissen fundoplication versus proton pump inhibitors for chronic and controlled gastroesophageal reflux disease: A 3-year prospective randomized controlled trial and economic evaluation. Value Health. 2011; 14(2):263–273. doi:10.1016/j.jval.2010.09.004.CrossRefGoogle ScholarPubMed
Thijssen, AS, Broeders, IA, de Wit, GA, Draaisma, WA. Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: A systematic review of the literature. Surg Endosc. 2011; 25(10):3127–3134. doi:10.1007/s00464-011-1689-y.CrossRefGoogle ScholarPubMed
Office for Health Improvement and Disparities, National Institute for Health and Care Excellence. Cost utility analysis: Health economic studies. Accessed June 3, 2023, www.gov.uk/guidance/cost-utility-analysis-health-economic-studies.Google Scholar
Mafi, JN, May, FP, Kahn, KL, et al. Low-value proton pump inhibitor prescriptions among older adults at a large academic health system. J Am Geriatr Soc. 2019; 67(12):2600–2604. doi:10.1111/jgs.16117.CrossRefGoogle Scholar
Reimer, C, Søndergaard, B, Hilsted, L, Bytzer, P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009; 137(1):80–87, 87.e1. doi:10.1053/j.gastro.2009.03.058.CrossRefGoogle ScholarPubMed
Reimer, C, Bytzer, P. Clinical trial: Long-term use of proton pump inhibitors in primary care patients – A cross sectional analysis of 901 patients. Aliment Pharmacol Ther. 2009; 30(7):725–732. doi:10.1111/j.1365-2036.2009.04092.x.CrossRefGoogle ScholarPubMed
Wilhelm, SM, Rjater, RG, Kale-Pradhan, PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013; 6(4):443–451. doi:10.1586/17512433.2013.811206.CrossRefGoogle ScholarPubMed
Ngamruengphong, S, Leontiadis, GI, Radhi, S, Dentino, A, Nugent, K. Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011; 106(7):1209–1218; quiz 1219. doi:10.1038/ajg.2011.113.CrossRefGoogle ScholarPubMed
Bavishi, C, Dupont, HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011; 34(11–12):1269–1281. doi:10.1111/j.1365-2036.2011.04874.x.CrossRefGoogle ScholarPubMed
Huber, MA, Nadella, S, Cao, H, et al. Does chronic use of high dose proton pump inhibitors increase risk for pancreatic cancer? Pancreas. 2022; 51(9):1118–1127. doi:10.1097/MPA.0000000000002145.CrossRefGoogle ScholarPubMed
Guo, H, Zhang, R, Zhang, P, et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front Pharmacol. 2023; 14:1129948. doi:10.3389/fphar.2023.1129948.CrossRefGoogle Scholar
Onwuzo, S, Boustany, A, Khaled Abou Zeid, H, et al. Prevalence and risk factors associated with inflammatory bowel disease in patients using proton-pump inhibitors: A population-based study. Cureus. 2023; 15(1):e34088. doi:10.7759/cureus.34088.Google ScholarPubMed
Jacobson, BC, Somers, SC, Fuchs, CS, Kelly, CP, Camargo, CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006; 354(22):2340–2348. doi:10.1056/NEJMoa054391.CrossRefGoogle ScholarPubMed
de Bortoli, N, Guidi, G, Martinucci, I, et al. Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: A comparative study. Dis Esophagus. 2016; 29(2):197–204. doi:10.1111/dote.12319.CrossRefGoogle ScholarPubMed
Yadlapati, R, Pandolfino, JE, Alexeeva, O, et al. The Reflux Improvement and Monitoring (TRIM) Program is associated with symptom improvement and weight reduction for patients with obesity and gastroesophageal reflux disease. Am J Gastroenterol. 2018; 113(1):23–30. doi:10.1038/ajg.2017.262.CrossRefGoogle ScholarPubMed
Harnik, IG. In the Clinic. Gastroesophageal Reflux Disease. Ann Intern Med. 2015; 163(1):ITC1. doi:10.7326/AITC201507070.CrossRefGoogle ScholarPubMed
Mc Cord, KA, Ewald, H, Agarwal, A, et al. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: Meta-research study. BMJ. 2021; 372:n450. doi:10.1136/bmj.n450.Google ScholarPubMed